● 10.31.21

Gemini version available ♊︎

●● When Corporate Media Cannot Tell the Difference Between EPO and EU

Posted in Deception, Europe, Patents at 8:41 am by Dr. Roy Schestowitz

Image: Bayer wins EU patent extension for best-selling Xarelto drugSeeding misinformation/falsehoods. EPO is not EU, so Reuters isn’t getting the very basic facts right; what can we expect from its Monsanto/Bayer reporting?

Image: Bayer wins EU patent extension for best-selling Xarelto drugSyndicating misinformation/falsehoods.

Image: Bayer wins EU patent extension for best-selling Xarelto drugGoing overseas too (other continents). EPO becoming better known for endless monopolies instead of helping patients, choosing corporate patents instead.

Image: Bayer Says Xarelto Gets Partial Extension of European PatentThis isn’t too bad, but it’s behind paywall and demands proprietary JavaScript/cookies. Moreover, the authors of that site (Bloomberg Law) were clearly hired for their patent maximalism (they recently added more of them). Reformist views are impermissible.

Image: Surprise success for Bayer blockbuster Xarelto at EPOInstead of writing reports, nowadays JUVE does ads for patent litigation firms, disguised as news articles (this is their new business model). Most of this past week’s JUVE stories were just ads for law firms, thinly veiled as reporting/journalism (we intentionally omit links to those, but we’re keeping internal records).

↺ JUVE

Image: EPO publishes final reasoning in G 1/21 video conferencing caseA longtime mouthpiece of EPO dictators and Team UPC, Amy Sandys, does that usual hogwash about EPO corruption in G 1/21. No investigation of underlying facts required, just revisionism. That’s where the money is.

EPO corruption in G 1/21

Summary: A look at the state of ‘journalism’ about patents and about the EPO specifically

↺ EPO

Share in other sites/networks: These icons link to social bookmarking sites where readers can share and discover new web pages.

Permalink > Image: Mail

 Send this to a friend

Permalink

↺ Send this to a friend

----------

Techrights

➮ Sharing is caring. Content is available under CC-BY-SA.